Banner

ADVANCEMENTS IN CANCER RESEARCH AND THERAPEUTICS CONFERENCE – ACRT 2026

March 25–27, 2026 | Boston, USA

We are honored to invite you to the Advancements in Cancer Research and Therapeutics (ACRT) 2026 international conference, taking place from March 25 to 27, 2026, in Boston, Massachusetts—a global hub for biomedical research and pharmaceutical innovation.

ACRT 2026 serves as a dynamic platform for leading minds in oncology, cancer biology, immuno-oncology, molecular diagnostics, translational medicine, and biopharmaceutical development to come together and explore the latest breakthroughs in cancer science and treatment. Read More

This globally significant event will convene a multidisciplinary community of:

  • Academic and clinical researchers
  • Medical and surgical oncologists
  • Biotech and pharmaceutical industry leaders
  • Translational scientists and drug development experts
  • Regulatory authorities and healthcare policymakers

Conference highlights include:

  • Scientific sessions on cancer genomics, precision oncology, and immunotherapy
  • Keynote lectures by global leaders in cancer research and drug discovery
  • Workshops on translational research, clinical trial design, and regulatory pathways
  • Short symposiums on emerging therapeutics, biomarkers, and companion diagnostics
  • Dedicated sessions for biotech innovations, AI in oncology, and pharma-academia partnerships
  • Robust networking forums and B2B engagement opportunities

Whether your focus is on basic research, clinical oncology, therapeutic development, or industry innovation, ACRT 2026 offers a unique opportunity to stay at the forefront of cancer treatment strategies and collaborative advancement.

Join us in Boston to shape the future of oncology—through discovery, innovation, and global collaboration.

Together, let’s advance the science that saves lives.

Plenaries and Keynotes

Ya Cheng
Tyler Jacks

MIT, Boston

Godai Miyaji
Rakesh K. Jain

Harvard Medical School and
Massachusetts General Hospital, Boston

Yuxi Fu
Ellen Pure

University of Pennsylvania, PA

Kodo Kawase
A Thomas Look

Dana-Farber Cancer Institute,
Harvard Medical School, MA

Kodo Kawase
Douglas Green

St Jude Children's Research Hospital, TN

Kodo Kawase
Kai Wucherpfennig

Dana-Farber Cancer Institute,
Harvard Medical School, MA

Kodo Kawase
John Quackenbush

Harvard T.H. Chan School of
Public Health, MA

Kodo Kawase
Ying-Chih Chang

AcroCyte Therapeutics Inc., Taiwan

Kodo Kawase
Khalid Shah

Harvard Medical School , MA

Kodo Kawase
XingXing Zang

Albert Einstein College of Medicine, NY

Kodo Kawase
John Bridgeman

CSO, Immunokey Ltd, UK